Sara Y. Tartof

7.6k total citations · 4 hit papers
137 papers, 4.3k citations indexed

About

Sara Y. Tartof is a scholar working on Epidemiology, Infectious Diseases and Health. According to data from OpenAlex, Sara Y. Tartof has authored 137 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Epidemiology, 61 papers in Infectious Diseases and 19 papers in Health. Recurrent topics in Sara Y. Tartof's work include SARS-CoV-2 and COVID-19 Research (35 papers), COVID-19 Clinical Research Studies (26 papers) and Pneumonia and Respiratory Infections (20 papers). Sara Y. Tartof is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (35 papers), COVID-19 Clinical Research Studies (26 papers) and Pneumonia and Respiratory Infections (20 papers). Sara Y. Tartof collaborates with scholars based in United States, France and Brazil. Sara Y. Tartof's co-authors include Vennis Hong, Bradley K. Ackerson, Luis Jódar, Jeff Slezak, Heidi Fischer, John M. McLaughlin, Srinivas Rao Valluri, Steven J. Jacobsen, Timothy B. Frankland and Owen D. Solberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

In The Last Decade

Sara Y. Tartof

126 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

2021 727 citations Sara Y. Tartof, Jeff Slezak et al. profile →
Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients

2021 470 citations Sara Y. Tartof et al. profile →
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California

2022 214 citations Joseph A. Lewnard, Vennis Hong et al. profile →
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system

2023 74 citations Joseph A. Lewnard, John M. McLaughlin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sara Y. Tartof United States	30	2.0k	1.2k	730	550	387	137	4.3k
Gili Regev‐Yochay Israel	36	2.8k 1.4×	1.4k 1.2×	684 0.9×	211 0.4×	439 1.1×	122	5.2k
Ping‐Ing Lee Taiwan	43	2.8k 1.4×	3.0k 2.5×	283 0.4×	539 1.0×	236 0.6×	238	7.0k
Woo Joo Kim South Korea	35	1.7k 0.8×	2.7k 2.3×	452 0.6×	159 0.3×	348 0.9×	292	5.1k
Joon Young Song South Korea	36	1.7k 0.8×	3.2k 2.7×	479 0.7×	170 0.3×	310 0.8×	301	5.6k
Hee Jin Cheong South Korea	34	1.6k 0.8×	2.8k 2.4×	471 0.6×	163 0.3×	312 0.8×	295	4.9k
Helena C. Maltezou Greece	46	2.9k 1.4×	2.1k 1.8×	1.5k 2.1×	397 0.7×	532 1.4×	234	6.5k
James Baggs United States	40	2.8k 1.4×	2.0k 1.7×	944 1.3×	230 0.4×	88 0.2×	135	5.9k
Nancy A. Chow United States	18	2.3k 1.1×	1.1k 1.0×	249 0.3×	638 1.2×	507 1.3×	50	4.5k
Hanan H. Balkhy Saudi Arabia	43	3.6k 1.8×	1.7k 1.5×	213 0.3×	895 1.6×	615 1.6×	154	8.0k
Aaron M. Harris United States	27	1.1k 0.5×	1.9k 1.6×	499 0.7×	399 0.7×	104 0.3×	65	4.3k

Countries citing papers authored by Sara Y. Tartof

Since Specialization

Citations

This map shows the geographic impact of Sara Y. Tartof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Y. Tartof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Y. Tartof more than expected).

Fields of papers citing papers by Sara Y. Tartof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Y. Tartof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Y. Tartof. The network helps show where Sara Y. Tartof may publish in the future.

Co-authorship network of co-authors of Sara Y. Tartof

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Y. Tartof. A scholar is included among the top collaborators of Sara Y. Tartof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Y. Tartof. Sara Y. Tartof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fischer, Heidi, Lei Qian, Zhuoxin Li, et al.. (2025). Development and validation of prediction algorithm to identify tuberculosis in two large California health systems. Nature Communications. 16(1). 3385–3385.

Aziz, Maliha, Daniel E. Park, Evangelos A. Dimopoulos, et al.. (2025). Zoonotic Escherichia coli and urinary tract infections in Southern California. mBio. 16(11). e0142825–e0142825.

Skarbinski, Jacek, Katia Bruxvoort, Heidi Fischer, et al.. (2025). Risk of Incident Tuberculosis Disease in a Large Integrated Health Care System in California, 2004–2022. Open Forum Infectious Diseases. 12(3). ofaf103–ofaf103. 1 indexed citations

Casey, Joan A., Lara Schwarz, Timothy B. Frankland, et al.. (2025). The 2025 Los Angeles Wildfires and Outpatient Acute Health Care Utilization. JAMA Health Forum. 6(11). e254632–e254632.

Patrick, Rudy, Parag Mahale, Bradley K. Ackerson, et al.. (2025). Respiratory syncytial virus vaccine uptake among adults aged ≥60 years in a large, integrated healthcare system in Southern California 2023–2024. Vaccine. 53. 127033–127033. 2 indexed citations

Weber, David J., Kanecia O. Zimmerman, Sara Y. Tartof, John M. McLaughlin, & Shanti Pather. (2024). Risk of COVID-19 in Children throughout the Pandemic and the Role of Vaccination: A Narrative Review. Vaccines. 12(9). 989–989.

Sandford, Ryan, Kelsey M. Sumner, Sara Y. Tartof, et al.. (2024). Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022. Influenza and Other Respiratory Viruses. 18(7). e13339–e13339.

King, Laura, Kristin L. Andrejko, Sarah Kabbani, et al.. (2024). Outpatient Visits and Antibiotic Use Due to Higher-Valency Pneumococcal Vaccine Serotypes. The Journal of Infectious Diseases. 230(4). 821–831. 3 indexed citations

Malden, Deborah E., Julianne Gee, Sungching Glenn, et al.. (2024). A Texting- and Internet-Based Self-Reporting System for Enhanced Vaccine Safety Surveillance With Insights From a Large Integrated Health Care System in the United States: Prospective Cohort Study. JMIR mhealth and uhealth. 12. e58991–e58991.

10.

Tartof, Sara Y., Jeff Slezak, Laura Puzniak, et al.. (2024). Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages. Open Forum Infectious Diseases. 11(7). ofae370–ofae370. 7 indexed citations

11.

Ku, Jennifer H, Heidi Fischer, Lei Qian, et al.. (2024). Latent Tuberculosis Infection Testing Practices in a Large US Integrated Healthcare System. Clinical Infectious Diseases. 78(5). 1304–1312. 3 indexed citations

12.

Casey, Joan A., Marianthi‐Anna Kioumourtzoglou, Amy Padula, et al.. (2024). Measuring long-term exposure to wildfire PM _2.5 in California: Time-varying inequities in environmental burden. Proceedings of the National Academy of Sciences. 121(8). e2306729121–e2306729121. 36 indexed citations

13.

Lewnard, Joseph A., Vennis Hong, Katia Bruxvoort, et al.. (2023). Burden of Lower Respiratory Tract Infections Preventable by Adult Immunization With 15- and 20-Valent Pneumococcal Conjugate Vaccines in the United States. Clinical Infectious Diseases. 77(9). 1340–1352. 7 indexed citations

14.

Lodise, Thomas P., Lie Hong Chen, Rong Wei, et al.. (2023). Clinical Risk Scores to Predict Nonsusceptibility to Trimethoprim-Sulfamethoxazole, Fluoroquinolone, Nitrofurantoin, and Third-Generation Cephalosporin Among Adult Outpatient Episodes of Complicated Urinary Tract Infection. Open Forum Infectious Diseases. 10(8). ofad319–ofad319. 3 indexed citations

15.

Flannery, Brendan, H. Keipp Talbot, Carlos G. Grijalva, et al.. (2022). Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021–2022 Influenza Season. Clinical Infectious Diseases. 76(8). 1358–1363. 32 indexed citations

16.

Malden, Deborah E., Sara Y. Tartof, Bradley K. Ackerson, et al.. (2022). Natural Language Processing for Improved Characterization of COVID-19 Symptoms: Observational Study of 350,000 Patients in a Large Integrated Health Care System. JMIR Public Health and Surveillance. 8(12). e41529–e41529. 17 indexed citations

17.

Elser, Holly, Sebastian T. Rowland, Sara Y. Tartof, et al.. (2022). Ambient temperature and risk of urinary tract infection in California: A time-stratified case-crossover study using electronic health records. Environment International. 165. 107303–107303. 11 indexed citations

18.

Lewnard, Joseph A., Katia Bruxvoort, Heidi Fischer, et al.. (2021). Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Medically Attended Lower Respiratory Tract Infection and Pneumonia Among Older Adults. Clinical Infectious Diseases. 75(5). 832–841. 31 indexed citations

19.

Innes, Gabriel K., Keeve E. Nachman, Alison G. Abraham, et al.. (2021). Contamination of Retail Meat Samples with Multidrug-Resistant Organisms in Relation to Organic and Conventional Production and Processing: A Cross-Sectional Analysis of Data from the United States National Antimicrobial Resistance Monitoring System, 2012–2017. Environmental Health Perspectives. 129(5). 57004–57004. 18 indexed citations

20.

Becerra-Culqui, Tracy A., Lina S. Sy, Bradley K. Ackerson, et al.. (2019). Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old. Vaccine. 38(2). 228–234. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact